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ABSTRACT 
 The magnetic properties and safety of dextran-coated superparamagnetic iron oxide 
nanoparticles (SPIONs) have facilitated their clinical use as MRI contrast agents and 
stimulated research on new applications for SPIONs in particle imaging and magnetic 
hyperthermia. The wider clinical potential of SPIONs, however, has been limited by their 
rapid removal from circulation via the reticuloendothelial system (RES). We explored the 
possibility of extending SPIONs circulatory time using fucoidan, a seaweed-derived food 
supplement, to inhibit RES uptake. The effects of fucoidan on SPION biodistribution were 
evaluated using ferucarbotran, which in its pharmaceutical formulation (Resovist®) targets 
the RES. Ferucarbotran was radiolabeled at the iron oxide core with technetium-99m (99mTc; 
t1/2 = 6 hours) or zirconium-89 (89Zr; t1/2 = 3.3 days). Results obtained with 99mTc-
ferucarbotran demonstrated that administration of fucoidan led to a 4-fold increase in the 
circulatory half-life (t1/2 slow) from 37.4 to 150 minutes (n = 4; P < 0.0001). To investigate 
whether a longer circulatory half-life could lead to concomitant increased tumor uptake, the 
effects of fucoidan were tested with 89Zr-ferucarbotran in mice bearing syngeneic 
subcutaneous (GL261) tumors. In this model, the longer circulatory half-life achieved with 
fucoidan was associated with a doubling in tumor SPION uptake (n = 5; P < 0.001). Fucoidan 
was also effective in significantly increasing the circulatory half-life of perimag®-COOH, a 
commercially available SPION with a larger hydrodynamic size (130 nm) than ferucarbotran 
(65 nm). These exciting findings indicate successful diversion of SPIONs away from the 
hepatic RES and show realistic potential for future clinical applications.  
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Dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) have many 
applications in biomedical research and a proven safety track record in clinical practice as 
contrast agents for magnetic resonance imaging (MRI) and as treatments for anemia.1-4 
Moreover, recent advances in magnetic hyperthermia therapy5 and novel imaging techniques 
such as magnetic particle imaging (MPI)6 and photoacoustic imaging7 have resulted in an 
increased interest for SPION-based contrast agents. However, SPIONs show preferential 
uptake by in situ macrophages within the reticuloendothelial system (RES) of the liver and 
spleen. Therefore, use of SPIONs in the clinic to date has mainly been to detect malignant 
lesions within these tissues8 or to image macrophage density in diseases such as 
atherosclerosis8-11 and type 1 diabetes.12 
The sequestration of SPIONs by the RES leads to very short circulation time and limits the 
wider imaging and therapeutic potential of SPIONs for non-RES targeted applications, such 
as tumor targeting through enhanced permeability and retention (EPR).13 Various methods to 
increase the half-life of SPIONs have been explored, many utilizing coatings (such as high 
density polyethylene glycol (PEG) polymers), 14-17 designed to sterically prevent hydrophobic 
and electrostatic interactions with components of the blood.14-18 The brush-like structures of 
the coat help to generate repulsive steric forces,19 reduce the formation of a protein corona20 
and thus protect nanoparticles from recognition by macrophages.21 Newer SPION 
modification technologies include bio-nano hybrid systems with biomimetic coatings, coating 
with ‘self’ peptides, or encapsulation within cell membranes.22-28  
An alternative strategy to prolong SPIONs circulatory time is to pre-treat with agents that 
inhibit the innate immune system components responsible for the rapid clearance of 
nanoparticles, thereby imposing a temporary block on circulatory removal and potentially 
allowing greater access of SPIONs to other tissues. This ‘blocking approach’ has the 
advantage that there is no requirement for complex chemical modification of SPIONs and it 
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can be readily applicable to SPIONs already approved for clinical use. A number of agents 
have been investigated as potential blockers to facilitate SPIONs accessibility, e.g. clodronate 
liposomes to deplete macrophages, gadolinium chloride (GdCl3) to inhibit Kupffer cell 
phagocytosis, complement inhibitors and the use of decoy nanoparticles to saturate 
macrophages prior to the injection of the therapeutic nanoparticles.29 Whilst there is some 
evidence of promise, none have yet been taken forward to the clinic and potential toxicity is a 
concern. For instance, dextran sulfate 500 (DSO4 500) can be used to block macrophage 
uptake of ferucarbotran, the SPION component of Resovist®,30 a clinical T2 MRI contrast 
agent designed to target the RES in order to detect focal liver cancerous lesions.31 However, 
DSO4 500 is not suitable for clinical development due to its toxic side effects (e.g. reversible 
thrombocytopenia and alopecia).32  
In the search for a clinically translatable alternative we turned our attention to fucoidans, a 
class of naturally occurring sulfated polysaccharides which are known ligands of the 
scavenger receptor class A (SR A),33 responsible for macrophage uptake of dextran-coated 
SPIONs.34-38 Fucoidans are composed mainly of fucose and sulfate ester groups and can be 
extracted from different species of brown seaweed (e.g. Fucus vesiculosus, Undaria 
pinnatifida and Macrocystis pyrifera) and marine invertebrates (e.g. sea urchins and sea 
cucumbers).39,40 Seaweed is eaten in many cultures and seaweed extracts are readily available 
in many over the counter food supplements.41 The safety profile of fucoidans makes them 
promising agents for clinical development and in recent years they have been subjected to 
intense research due to their versatile biological applications.39,40, 42 Fucoidans are reported to 
possess antioxidant, antiviral, anticoagulant and anti-inflammatory properties, and to 
modulate blood lipid levels.39,40 Fucoidan has also been studied as an anticancer agent43 and 
has been investigated in osteoarthritis, stem cell modulation, kidney disease and liver 
disease.41 
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In this study, we use radiolabeled SPIONs and in vivo preclinical nuclear imaging to 
investigate the biodistribution of dextran-coated SPIONs. We apply these methods to 
evaluate the potential of fucoidans to increase the circulatory presence of SPIONs and 
enhance tumor uptake.   
 
RESULTS AND DISCUSSION   
In vitro internalization and inhibition of ferucarbotran uptake by macrophages  
The uptake of ferucarbotran was first evaluated in vitro using the murine 
monocyte/macrophage cell line RAW 264.744 that has been extensively employed in the 
study of the interactions of nanoparticles, specifically SPIONs, with macrophages.35-37, 45 
Ferucarbotran uptake by the cells was measured quantitatively by the ferrozine iron assay46 
and visualized using Prussian blue (Perls’) staining.47-51 Internalization of electron-dense 
SPIONs by cells was confirmed by transmission electron microscopy (TEM). The results, 
shown in Figure 1A, revealed that macrophage iron uptake increased in a dose dependent 
manner in proportion to the concentration of ferucarbotran incubated with the cells. This is 
consistent with the endocytosis of SPIONs by macrophages observed by others36, 52 and 
thought to be mainly mediated via SR A34-38 and clathrin-mediated endocytosis.35,36 Studies 
investigating the role of other carbohydrate recognition pathways in SPION uptake indicate 
that, whilst mannose receptors (CD206) and SIGNR1 can mediate the uptake of bacterial 
polysaccharides such as dextrans, these receptors do not appear to be involved in the uptake 
of dextran coated SPIONs.37 
Perls’ staining is a long-established method to stain SPIONs in cells and tissues giving dense 
blue aggregates. Thus, the presence of blue aggregates within RAW 264.7 cells incubated 
with ferucarbotran (Figure 1B) was taken to demonstrate the presence of SPIONs. TEM was 
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used to show the internalization of ferucarbotran, which appears within the cells as 
aggregates rather than as single particles (Figure 1C). All intracellular nanoparticles detected 
were in cytoplasmic vesicles and none were visualized within the nucleus. Low magnification 
TEM images of macrophages showed invagination of the cell membrane (Figure 1D), 
indicating nanoparticle aggregates in the process of being endocytosed; non-internalized 
nanoparticles were visualized on the cell surface membrane. To test if the electron dense 
aggregates were SPIONs, energy dispersive X-ray (EDAX) microanalysis of unstained TEM 
slides was performed (Figure 1E-F). The presence of elemental iron indicated that the 
aggregates were indeed SPIONs, as opposed to other electron dense structures found within 
cells.  
Fucoidans from 3 different species of seaweed: Fucus vesiculosus (FVF), Macrocystis 
pyrifera (MPF) and Undaria pinnatifida (UPF) were evaluated, in comparison with DSO4 
500, for ability to reduce uptake of ferucarbotran by RAW 264.7 macrophages. Cells were 
pretreated with the fucoidans at concentrations of 30 and 60 µg/mL, followed by incubation 
with ferucarbotran at 0.1, 0.5 and 1 mgFe/mL. Results (Figure 1G), demonstrated that pre-
treatment with fucoidans led to a significant reduction in the uptake of ferucarbotran at all 
tested conditions. These results support published literature on the in vitro blocking effect of 
both DSO4 50053 and fucoidan54 on nanoparticle uptake by macrophages.  
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Figure 1. Internalization of ferucarbotran by macrophages. (A) Ferrozine assay was used 
to measure the uptake of ferucarbotran by macrophages. Bars represent the average of 3 
replicates; error bars are for standard deviation. (B) Prussian blue staining showed the 
presence of ferucarbotran as blue aggregates inside the cells compared to none visible in the 
untreated control. Scale bar = 20 µm (C) TEM micrographs showing electron dense 
cytoplasmic vesicles containing the SPIONs with none detected in the nucleus (N) or the 
untreated control. (D) Low magnification TEM image (6000x) showed some nanoparticles 
being endocytosed by macrophages (black arrow) while others appeared either on the surface 
of the cells attached to the cell membrane (black arrow heads) or inside the cells (white arrow 
heads). (E-F) EDAX microanalysis detected iron peaks (red arrow, E) in the vesicles 
containing the rod-shaped aggregates compared to no iron peak (red arrow, F) in other 
uniformly shaped electron dense vesicles inside the cells. (G) In vitro blocking effect of the 
three different fucoidans on the uptake of ferucarbotran by RAW 264.7 macrophages, 
compared to DSO4 500. 
 
In vivo effect of fucoidan on the circulation time and biodistribution of ferucarbotran  
Preliminary in vivo experiments were conducted using NIR-labeled ferucarbotran, a method 
previously established as suitable to measure blood concentrations of this nanoparticle.30 
These experiments confirmed that all three fucoidans were capable of significantly increasing 
the blood levels of ferucarbotran, demonstrable at one hour following particle injection. FVF 
was at least as effective as the other fucoidans (Supplementary Figure S1) and was taken 
forward because it was the best characterized and least poly-dispersed fucoidan (see 
supplementary data, tables S2-S4). An in vivo dose of 15 mg/kg was chosen based upon 
existing safety and tolerability data (Supplementary data, Biological safety and dose 
justification of Fucus vesiculosus (FVF)). To quantitate the effects of FVF on biodistribution, 
ferucarbotran was radiolabeled with the gamma-emitting radioisotope technetium-99m 
(99mTc) to track its organ uptake using SPECT/CT and by ex vivo gamma counting. The 
radiolabeling method exploits the high affinity of a bifunctional bisphosphonate chelator 
(dipicolylamine-alendronate; DPA-Ale) for the metal oxide core of ferucarbotran (Figure 2) 
and is an established technique previously shown to be capable of maintaining the original 
physicochemical properties of iron oxide nanoparticles (Supplementary Table S5).55,56 This 
method has been successfully used in several studies to evaluate the biodistribution of 
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SPIONs in vivo and shows negligible leakage of 99mTc-DPA-ale in vivo (Supplementary 
Figure S2).55-59 Labeling SPIONs using radionuclides has significant advantages over other 
imaging strategies (e.g. MRI or optical imaging) as it allows accurate quantitative 
information of their biodistribution at the whole-body level. 
 
Figure 2. Schematic representation of ferucarbotran radiolabeling with 99mTc using a 
radiolabeled bifunctional bisphosphonate (99mTc-DPA-ale). The linker (DPA-ale; inset) is 
radiolabeled with 99mTc at the dipicolylamine (DPA) group while the bisphosphonate group 
effectively binds to the iron oxide core of the SPION.  
 
Balb/c mice were injected i.v. with 99mTc–ferucarbotran (15-30 MBq, 34.8 µg Fe), 
immediately preceded either by an i.v. injection of FVF (FVF (+); n = 5) or PBS (FVF (-); n 
= 5). Selected animals from both groups were scanned using SPECT/CT for 80 minutes 
following injection (4 × 20 minutes scans) before being sacrificed and the organs harvested. 
To investigate circulation time, blood samples were obtained at set time points post 
ferucarbotran injection; either pretreated with FVF (n = 4) or PBS (n = 4). 
The results showed a significant change in the pharmacokinetic behavior of ferucarbotran in 
the FVF-treated mice when compared to the controls (Figure 3A). The circulation half-life 
(t1/2) and the area under the curve (AUC), calculated using a two-compartment 
pharmacokinetic model from the blood sampling results, revealed that FVF increased the t1/2 
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(slow) 4-fold, from 37.4 to 150 minutes (n = 4; P < 0.0001). In addition, the AUC, 
representative of the total exposure of the animals to systemically circulating SPIONs, 
increased 3.5-fold, from 1615 ± 93 %ID･min/g to 5699 ± 138 %ID･min/g (n = 4; P < 
0.0001). 
SPECT/CT imaging (Figure 3B) showed that in the control group (FVF (-)), 99mTc-
ferucarbotran was clearly visualized in the liver 20 minutes post injection with minor 
presence in the bloodstream. In contrast, in FVF treated mice (FVF (+)), 99mTc–ferucarbotran 
was mainly detected within the blood pool. At 80 minutes post injection, 99mTc–ferucarbotran 
was visualized mainly within the liver for FVF (-) mice, whereas in FVF (+) mice, a blood 
pool presence was still observed, with only minor uptake in the liver. These findings support 
the hypothesis that FVF is able to block the uptake of 99mTc–ferucarbotran by liver 
macrophages, and significantly prolong the circulatory time of the SPION. The signal 
observed in the bladder of FVF (+) mice is likely to correspond to a small fraction of excreted 
metabolized radionuclide, as previously reported for long-circulating PEGylated iron oxide 
nanoparticles radiolabeled using this method.55 
Following imaging studies, ex vivo 99mTc–ferucarbotran organ counts were performed and 
expressed in percentage of injected dose per gram of tissue (%ID/g). Consistent with the 
findings on SPECT/CT, the most striking differences were the decreased %ID/g in liver with 
concomitant increases in both blood and spleen (Figure 3C-D). Furthermore, tissue to blood 
ratios demonstrated significant differences in the uptake within the liver, with a liver to blood 
ratio of 8.3 ± 2.8 compared to only 0.5 ± 0.13 in the FVF (+) counterpart (n = 5; P < 0.01).  
However, there was no significant difference in tissue to blood ratios for spleen, indicating 
that the increased %ID/g value for this organ was due to the higher blood levels. All other 
tissues showed similar tissue to blood ratios in the FVF (+) vs. FVF (-) groups. After 
radioactive decay, sections of the excised livers were stained using Prussian blue to determine 
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whether the reduced liver uptake of SPIONs in the FVF treated mice could be visualized 
histologically. The resulting images indicated that staining appeared to be lower and less 
intense in the livers of mice pretreated with FVF (Supplementary Figure S3A).  Digital image 
analysis, performed to obtain a less subjective measurement, supported the observation that 
Perls’ stain uptake in FVF treated mice (n = 2) was reduced overall and less intense than in 
the control mice (n = 2) (Supplementary Figure S3B). These results further support the 
hypothesis that FVF blocks the uptake of dextran-coated SPIONs, such as ferucarbotran, 
within the liver, although the mechanism by which SPION uptake is inhibited remains 
unclear. As ligands of SR A,33 fucoidans could simply compete with and inhibit SR A uptake 
of dextran-coated SPIONs by macrophages. However, other receptors and immune 
recognition pathways may also be involved, leading to complex uptake mechanisms. 
Furthermore, SPIONs are known to develop a ‘corona’ of proteins when exposed to 
biological milieu, which can influence both their biocompatibility and biological fate.60,61 
There is evidence that the presence of complement proteins within this corona can affect the 
interactions of SPIONs with cells of the immune system,62 directly influencing the 
interactions of the particles with immune cells, including internalization via scavenger 
receptors.63,64  
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Figure 3. Biodistribution of 99mTc-ferucarbotran in Balb/c mice. (A) Blood time-activity 
curve of 99mTc–ferucarbotran in the presence (+) and absence (-) of FVF (n = 4 per group). 
The data was fitted to a two-compartment pharmacokinetic model that allowed the 
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calculation of the circulation half-life (t1/2) and area under the curve (AUC) values for each 
group and showing a significant increase in circulation time in the FVF treated group. (B) 
Maximum intensity projection (MIP) images with transverse slices centered at the heart 
(bottom). H: heart; L: liver; S: Spleen; B: bladder and K: kidneys. (C-D): Biodistribution of 
99mTc-ferucarbotran in post-mortem harvested organs 80 minutes following SPION injection 
(n = 5). *** P < 0.0001 and ** P < 0.01 compared to FVF (-) as measured with unpaired two-
tailed t-test. Bars represent means and error bars are for the standard error of means (SEM). 
Full organ data can be found in Supplementary Tables S8 and S9.  
 
Evaluating the effect of FVF blocking on the accumulation of SPIONs in tumors  
In order to track ferucarbotran for longer time periods, the iron-oxide cores of the SPIONs 
were directly radiolabeled with the positron-emitter zirconium-89 (89Zr; t1/2 = 3.3 days), using 
a recently described method shown schematically in Figure 4.65 This method caused an 
increase in the hydrodynamic diameter of ferucarbotran following labeling (z-average: 53.6 ± 
0.1 to 127 ± 14 nm) as determined by dynamic light scattering (DLS) (Supplementary Table 
S6). Despite this increase in hydrodynamic size, 89Zr-ferucarbotran remained in dispersion 
with no evidence of precipitation. This increase in size could result in more rapid circulatory 
clearance as larger SPIONs are known to possess shorter half-lives66 and we predicted it 
could be more challenging to maintain 89Zr-ferucarbotran in circulation, compared with 
99mTc-ferucarbotran. To evaluate whether FVF could meet this challenge and also lead to a 
concomitant increase in accumulation of SPIONs within tumors, the subcutaneous GL261 
syngeneic C57BL/6 mouse model was utilized.67 GL261 has been extensively used to assess 
the efficacy of anti-cancer therapies including immunotherapies for the treatment of 
gliomas.68,69 Another advantage of utilizing C57BL/6 mice was to test whether FVF is also 
active in strains of mice other than Balb/c.  
 89Zr-ferucarbotran was injected i.v. into tumor bearing mice either without FVF (FVF (-); n = 
5), immediately preceded by FVF (FVF (+) (pre-injection); n = 5) or with FVF included in 
the SPION formulation (FVF (+) (co-injection); n = 5). Blood samples were taken at set time 
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intervals, PET/CT imaging was performed at 30 minutes and 24 hours post injection and ex 
vivo organ counting performed at 24 hours.  
 
Figure 4. Schematic representation of the direct radiolabeling of ferucarbotran with 
89Zr. 
 
Results showed that, consistent with the observed increase in hydrodynamic size, the 
circulatory clearance of 89Zr-ferucarbotran occurred faster than that previously observed for 
99mTc-ferucarbotran (Figure 5A). Nonetheless, FVF was able to increase 89Zr-ferucarbotran 
circulation half-life, with a 2.3-fold increase in t1/2 (slow), from 16.8 to 39.7 minutes (n = 3; P 
= 0.0006) and a 6-fold increase in AUC (from 176 ± 14 to 1079 ± 89; n = 3; P = 0.0006). 
Results showed there was no significant difference between the FVF (+) (pre-injection) and 
FVF (+) (co-injection) groups (Figure 5A) (Note: FVF (+) pharmacokinetic data refers to the 
pre-injection method only, as the co-injection method data could not be fitted to the two-
compartment pharmacokinetic model). 
PET images were obtained at 30 minutes post-injection (Figure 5B), showing observable 
differences between FVF (+) and FVF (-) groups in liver uptake, with no PET signal detected 
in the blood pool in any of the groups. A lower 89Zr-ferucarbotran signal was observed by 
PET/CT in the liver of FVF (+) mice with higher observed signal in the spleen at both 30 
minutes and 24 hours following injection. Within tumors, a higher signal was observed in the 
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tumors of FVF (+) mice at both time points. Ex vivo organ counting (%ID/g) at 24 hours 
showed patterns of uptake consistent with PET/CT observations with significantly higher 
%ID/g in the blood (P = 0.0432), spleen (P = 0.0017) and heart (P = 0.0082) of FVF treated 
mice (pre-injection) (Figure 5C-D). Concomitant with the increased circulatory presence, 
administration of FVF also led to a 2-fold increase in the tumor accumulation of SPIONs (P 
< 0.001). In summary, these results indicate that blocking SPION uptake into RES 
macrophages leads to increased circulatory presence and greater tumor uptake.  
Within the tumor, fucoidan could react with tumor associated macrophages (TAMs) giving 
rise to a number of effects that warrant further study. TAMs are phenotypically plastic and 
their roles in the tumor microenvironment are complex and contrasting.  They can promote 
cancer-related inflammation and tumor progression by a number of mechanisms and they can 
also exhibit antitumor effects.70 SPIONs have been shown to influence macrophage 
polarization71,72 and may consequently inhibit tumor growth.71 In this instance, the potentially 
undesirable effects of inhibiting SPION uptake by TAMs should be considered.  Independent 
of its SPION-blocking function, fucoidan could affect tumor growth via direct interaction 
with SRs on the cell surface of TAMs. SR has been reported to contribute to 
immunosuppression43 and promote tumor progression73 and the interactions between 
fucoidan and SR within the tumor microenvironment have been implicated as contributory to 
fucoidan’s purported anti-cancer effects.43 Other studies suggest that fucoidan binding to SR 
leads to dendritic cell activation, enhancing the immune response. Furthermore, fucoidan has 
been shown to possess immune-stimulating effects on both DCs74-77 and natural killer (NK) 
cells78,79 and therefore could also enhance anticancer immunity by activating immune cells 
and stimulating production of immunostimulatory cytokines.43  
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Figure 5. Blood clearance and systemic biodistribution of 89Zr-Ferucarbotran in tumor 
bearing C57BL/6 mice. (A) Blood time-activity curve in the presence and absence of FVF. 
(B) Maximum intensity projection images (MIP) with transverse slices centered at the liver 
and tumor taken at 30 minutes and 24 h post injection of 89Zr-ferucarbotran. Since no 
significant difference was observed between the pre-injection and the co-injection FVF-
treated mice; ‘FVF (+)’ refers to the pre-injection group in Figure 5B. (C-D): Biodistribution 
of 89Zr-ferucarbotran in select post-mortem harvested organs at 24 h post injection. Inset 
shows the tumor uptake. *** P ≤ 0.001, ** P < 0.01 and * P < 0.05 compared to FVF (-) as 
measured using an unpaired two-tailed t-test. Bars represent mean values and error bars are 
for the standard error of the mean (SEM). Full organ data can be seen in Supplementary 
Tables S10 and S11.  
 
Testing the effects of fucoidan on the uptake of perimag® SPIONs in vitro 
To determine whether the blocking effects of fucoidan were applicable to other SPIONs, FVF 
was tested on perimag® (Table 1), a family of SPIONs with favorable properties for 
magnetic resonance and magnetic particle imaging, stem cell tracking, and hyperthermia 
therapy.80-81 There are a number of differences between perimag® SPIONs and 
ferucarbotran: ferucarbotran is coated with carboxydextran and has a hydrodynamic diameter 
of approximately 65 nm, whilst perimag®-COOH is significantly larger (130 nm) and has a 
plain dextran coating (perimag®-plain) subsequently functionalized with carboxylic acid 
groups. Thus, perimag® can be controlled in terms of the quantity of surface carboxylic acid 
groups, providing a versatile basis for SPION development. Perimag®-plain can also be 
functionalized with positively charged amine groups (perimag®-NH2). 
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Table 1. SPIONs investigated in this study. 
Reagent Name Coat Supplier Size from manufacturer 
Surface Charge 
(Zeta-potential) * 
Ferucarbotran  Carboxydextran Meito-Sangyo, Japan 65 nm 
-20.0 ± 11.0 mV 
Perimag®-plain Dextran 
Micromod 
GmbH, 
Germany 
130 nm -1.47 ± 5.01 mV 
Perimag®-COOH 
Dextran 
functionalized 
with carboxylic 
acid groups 
130 nm 
 
-9.94 ± 3.38 mV 
Perimag®-NH2 
Dextran 
functionalized 
with amine 
groups 
130 nm 
 
13.00 ± 3.72 mV  
 
* Measured in 5 mM NaCl on a Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) 
 
First, the interaction of perimag® SPIONs with RAW 264.7 macrophages was investigated 
and the effects of fucoidan on this interaction evaluated. The results (Figure 6) revealed that 
all perimag® SPIONs had lower macrophage uptake than ferucarbotran, with only 
perimag®-COOH showing strong uptake. Cellular uptake of the near-neutral perimag®-plain 
and the positively charged perimag®-NH2 was low irrespective of whether fucoidan or DSO4 
500 were present. These in vitro findings are consistent with the predisposition of 
macrophages to take up negatively charged particles.82 The relatively lower macrophage 
uptake of perimag®-COOH compared to ferucarbotran could be attributable to the 
differences in their charge or hydrodynamic diameters as previously observed with other 
particles.83 
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Figure 6. Testing the effect of fucoidan (FVF) and dextran sulfate (DSO4 500) on the 
uptake of different SPIONs by RAW 264.7 macrophages. Equimolar concentrations (0.17 
µM) of FVF and DSO4 500 were used. *DSO4 500 led to the precipitation of perimag®-
NH2. Bars represent the mean value and error bars are for standard deviation.   
 
Treatment with FVF or DSO4 500 significantly reduced macrophage uptake of perimag®-
COOH providing justification to test whether FVF would be an effective RES blocker of 
perimag®-COOH in vivo. As well as being predisposed to uptake by macrophages, 
negatively charged SPIONs show promise for clinical development because they possess 
superior biocompatibility compared to their positively charged and neutral counterparts.84  
 
Testing the effect of FVF on the biodistribution of perimag®-COOH 
Perimag®-COOH was radiolabeled with 89Zr as described for ferucarbotran (Figure 4). The 
perimag® SPIONs showed superior labelling stability as, in contrast to 89Zr-ferucarbotran, 
89Zr-perimag®-COOH did not show any significant change in size when analyzed by DLS 
(Supplementary Table S7). 89Zr-perimag®-COOH was injected i.v. into C57BL/6 mice either 
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alone (FVF (-), with a preceding injection of fucoidan (FVF (+) pre-injection) or in 
combination with fucoidan (FVF (+) co-injection). As described previously, blood samples 
were taken at pre-determined time points, mice were imaged by PET/CT at 80 minutes and 
24 hours and organ counts were conducted at 80 minutes and 24 hours following injection.  
The results showed a clear change in the pharmacokinetic behavior of 89Zr-perimag®-COOH 
in the FVF (+) mice compared to FVF (-) control (Figure 7A). Similar to the results observed 
using 99mTc–ferucarbotran and 89Zr–ferucarbotran, FVF caused an increase in the systemic 
circulation of 89Zr-perimag®-COOH in FVF (+) mice, with a calculated AUC of 484 ± 44 
%ID･min/g and 566 ± 76 %ID･min/g (n = 3; P = 0.18) for the FVF pre-injection and FVF 
co-injection groups, respectively, compared to 183 ± 14 for the FVF (-) control. Once again, 
this result demonstrated that there was no significant difference observed between the FVF 
pre-injection and the co-injection groups. Overall, the administration of FVF led to a 2.6-fold 
increase in the AUC of 89Zr-perimag®-COOH and a 1.6-fold increase in the circulation half-
life (t1/2 slow) from 18.9 minutes (FVF (-)) to 30.7 minutes (FVF (+) pre-injection) (n = 3; P 
= 0.004). PET/CT images and the ex-vivo biodistribution data (Figure 7B-G) revealed that 
89Zr-perimag®-COOH cleared faster than 99mTc–ferucarbotran. For all groups, at 80 minutes, 
a very low %ID/g remained within the blood pool with the majority of the SPIONs observed 
within the liver and the spleen.  This could be explained by the larger hydrodynamic diameter 
of perimag®-COOH compared to ferucarbotran (65 nm vs. 130 nm) resulting in faster 
clearance by the RES. Nonetheless, PET imaging appeared to show a lower signal in the liver 
of mice treated with FVF compared to the FVF (-) controls. Tissue to blood ratios at 80 
minutes showed a lower ratio in the liver for mice treated with FVF, although these 
differences were not found to be statistically significant. In summary, FVF successfully 
increased the circulatory half-life of perimag®-COOH confirming that this finding was not 
limited to ferucarbotran. 
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Figure 7. Biodistribution of 89Zr-perimag®-COOH in C57BL/6 mice. (A) Blood time-
activity curve in the presence and absence of FVF. The data was fitted to a two-
compartmental pharmacokinetic model that allowed the calculation of the circulation half-
lives (t1/2) and areas under the curve (AUC) values for each group (Inset: comparison of the 
pre- and co-injection methods showing no difference in the effect of FVF. Note linear scale in 
y-axis) (B, C) Maximum intensity projection images (MIP) with transverse slice (bottom) 
centered at the heart and liver taken at 80 minutes (B) and 24 hours (C) post injection of 89Zr-
perimag®-COOH. FVF (+) refers to the pre-injection group. (D-G): Biodistribution of 89Zr-
perimag®-COOH in post-mortem harvested organs at 80 min (D) and 24 h (E). *** P = 
0.001, ** P = 0.01 and * P < 0.05 compared to FVF (-) as measured with unpaired two-tailed 
t-test. Bars represent means and error bars are for the standard error of means (SEM). Full 
organ count data is available in Supplementary Tables S12, S13, S14 and S15. 
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CONCLUSIONS 
Rapid circulatory clearance is considered one of the major limitations in the development of 
nanoparticles. We report a perspective to prolong the half-life of one class of nanoparticle, 
dextran-coated SPIONs, without the need to change their physicochemical characteristics. 
In summary, we used two different radiolabeling strategies (99mTc and 89Zr) to trace two types 
of SPIONs (ferucarbotran and perimag®-COOH) with high sensitivity in vivo. By employing 
fucoidan, a naturally occurring polysaccharide, we prolonged the circulation half-lives of 
SPIONs, increased their systemic presence (AUC) and doubled their accumulation in tumors. 
Fucoidan is readily available as a natural food supplement with no reported toxic side effects 
either in vitro or in vivo.43 
There are ongoing discussions regarding the effectiveness of nanoparticle delivery, with 
concern that over the last decade the average delivery of systemically administered particles 
to tissues of interest has remained below 1% of the administered dose, despite the utility of 
both passive and active targeting 85,86 ; sequestration of particles by the RES is a major factor 
in this low delivery. By prolonging the circulation time, fucoidan could work synergistically 
with passive and active targeting technologies, providing a generic means to improve the 
delivery of many different nanoparticles. 
Removal of nanoparticles by the RES leads to a lack of efficacy because the particles are 
sequestered away from the intended sites of delivery and into the liver and spleen.22, 87 
Approaches for RES avoidance have long been sought and is most commonly tackled by 
modifying SPIONs coatings with hydrophilic polymer coatings (e.g. PEG, PVP, poloxamines 
and poloxamers) to prolong circulation times.88 However, modifying the surface coatings in 
this way changes the physical properties of the nanomaterial and is therefore unsuitable when 
using clinical products with well-studied safety profiles. By overcoming the rapid RES 
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clearance of SPIONs, the work presented in this paper could provide a step towards the 
clinical development of nanomedicines.  
 
EXPERIMENTAL SECTION  
Materials. Ferucarbotran was purchased from Meito Sangyo Co. LTD., Tokyo, Japan. 
Perimag® was obtained from Micromod Partikeltechnologie GmbH.  All other materials 
were purchased from Sigma Aldrich (Dorset, UK) unless otherwise specified. 
Cell uptake experiments. All in vitro experiments were repeated at least 3 times on 3 
different days for reproducibility and representative data is shown in the results section. 
RAW 264.7 cells were seeded at 2 x 105 cells/well in 24-well plates (Corning®) and left to 
attach overnight. On the following day, the cells were treated with ferucarbotran at three 
different concentrations (0.1, 0.5, 1 mgFe/mL) for 4 hours at 37°C. Cells were then washed 3 
times with cold PBS to remove excess unbound SPIONs.  Next, the cells were lysed with 200 
µL of 50 mM sodium hydroxide (NaOH) and the intracellular iron content was determined 
using the colorimetric ferrozine assay46 and then compared to a standard curve of 
ferucarbotran samples of known iron concentrations. For the ferrozine assay; 100 µL of each 
cell lysate was aliquoted into an Eppendorf tube then 100 µL of dH2O (solvent of 
ferucarbotran) was added. 100 µL aliquots of serial dilutions of ferucarbotran at 0.15 - 20 
µgFe/mL were prepared from the stock solution and then 100 µL of 50 mM NaOH was added 
to each tube. Next, to each tube of cell lysates and ferucarbotran, 100 µL of freshly prepared 
iron releasing solution (equal volumes of 1.4 M HCl and 4.5% (w/v) potassium permanganate 
(KMnO4)) was added. The mixture was incubated for 2 hours at 60 °C in a water bath before 
being cooled down for 10 minutes followed by the addition of 30 µL of iron detection 
solution (6.5 mM neocuproine, 6.5 mM ferrozine, 1 M ascorbic acid and 2.5 M ammonium 
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acetate in water). The tubes were then further incubated for 30 minutes to allow for maximum 
color development. 100 µL of each tube was then aliquoted into a 96-well plate (Corning®) 
and the absorbance was measured at 550 nm on Varioskan™ Flash Multimode reader 
(Thermo Scientific). The concentration of each sample was extrapolated from the standard 
curve and the amount of iron per cell (picograms iron per cell (pgFe/cell)) was calculated as 
follows: 
 
Perl’s Prussian blue staining. Cells were seeded and treated with 0.5 mgFe/mL of 
ferucarbotran for 4 hours as described above. Next, the cells were washed thoroughly with 
cold PBS and fixed using a solution of 2% formalin and 2.5% glutaraldehyde in PBS for 10 
minutes at room temperature. The cells were then washed with PBS and stained with a 
freshly prepared Prussian blue staining solution (4 g potassium hexacyanoferrate (II) 
trihydrate dissolved in 20 mL dH2O + 20 mL 2% HCl) for 10 minutes and counterstained 
with eosin, mounted with DPX and imaged with 100x oil immersion lens using Carl Zeiss 
Axioskop MOT 2 microscope (Carl Zeiss, Germany). 
Transmission Electron Microscopy (TEM) and Energy Dispersive X-ray microanalysis 
(EDAX). Cells were seeded at 2 x 105 cells/well in 6-well plates (Corning®) and allowed to 
attach overnight. Next day the cells were treated with 0.5 mgFe/mL ferucarbotran for 4 hours 
before being washed 3 times with cold PBS. Then the cells were fixed in 1.5% 
glutaraldehyde/1% paraformaldehyde/PBS pH 7.4, for a minimum of 2 hours, and stored at 
4°C until processing for TEM. Fixed cells were centrifuged to form a pellet in 0.5 mL 
Eppendorf. The cells were then washed with two changes of phosphate buffer (Oxoid) and 
post-fixed with osmium tetroxide solution (1% osmium tetroxide (Analar BDH) + 1.5% 
potassium ferricyanide (BDH) in PBS (Oxoid)). The cells were resuspended during each 
pgFe / cell = Concentration (µgFe /ml)number of cells / ml X 10
6
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change of solution and allowed to stand for 10 minutes, before removal of the supernatant 
and addition of the next processing solution. Following this, the cells were washed using 
several changes of distilled water to remove the osmium tetroxide and dehydrated using 
increasing alcohol concentrations of 30%, 50%, 70%, 90% and 100%. After dehydration, the 
samples were left in 50% alcohol / 50% Lemix (TAAB) epoxy resin mixture on a mixer 
overnight to infiltrate with resin. The samples were then placed in 100% Lemix resin for a 
minimum of 4 hours, embedded in fresh Lemix Resin and polymerized at 70 °C overnight. 
Semi-thin (1µm) sections were cut using glass knives on a Reichert-Jung Ultracut microtome, 
collected on glass microscope slides and stained using Toluidine Blue solution (1% Toluidine 
Blue (Raymond Lamb) with 0.2% Pyronin (Raymond Lamb) in 1% sodium tetraborate 
(Analar BDH)). Ultrathin sections were cut using a diamond knife (Diatome) and collected 
on 300HS, 3.05 mm copper grids (Gilder). The ultrathin sections were stained using saturated 
alcoholic uranyl acetate (UA) (TAAB) for 5 minutes followed by Reynold’s lead citrate, also 
for 5 minutes. Sections examined with EDAX were not stained with UA or lead. The sections 
were viewed and photographed using a Philips CM120 transmission electron microscope 
fitted with EDAX DX-4 microanalytical system for X-ray microanalysis of the samples. 
Cell blocking experiments. Cells were pre-treated with the fucoidans or DSO4 500 at either 
30 or 60 µg/mL for 15 minutes before being challenged with ferucarbotran (0.1, 0.5, 1 
mgFe/mL) for 4 hours at 37°C. All experiments were performed in triplicate and repeated on 
three separate occasions on different days. For blocking experiments with FVF and DSO4 
500 at equimolar concentrations, cells were pretreated with 0.17 µM of either blocker before 
adding 0.5 mgFe/mL of the SPIONs (ferucarbotran, perimag®-plain, perimag®-COOH or 
perimag®-NH2) for 4 hours. Then cells were lysed and the intracellular iron content 
determined using ferrozine assay as described above.  
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In vivo experiments. All in vivo experiments were performed using mouse models in 
compliance with licenses issued under the U.K. Animals (Scientiﬁc Procedures) Act 1986 
after local ethical committee review. All mice used were female Balb/c or C57BL/6 (Charles 
River Laboratories, UK) with an average weight of 20 g at the start of the experiments. 
SPIONs and fucoidans were prepared in PBS and sterile filtered (using 0.22 µm syringe 
filter) under a cell culture hood prior to injection, in order to minimize bacterial 
contamination. All injections were administered intravenously through tail veins. Fucoidans 
were injected at 15 mg/kg.  
Radiolabeling of ferucarbotran with technetium-99m (99mTc). Technetium-99m-
dipicolylamine-alendronate (99mTc-DPA-ale) linker was synthesized as previously 
described.56-57 The linker was purified using a C18 Sep-Pak® light column, yielding 200 µL 
of 460 MBq of 99mTc-DPA-ale in dH2O. Then 3 µL of ferucarbotran (0.174 mgFe) was added 
and the mixture was incubated at 40 °C for 30 minutes while shaking. The vial was then 
cooled to room temperature and the contents transferred to an Amicon® Ultra 0.5 mL 
centrifugal filter with a 10 kDa cut off that had been previously washed with 3 × 500 µL of 
dH2O. The filter was centrifuged at 11,000 x g for 3 minutes. The remaining retained solution 
contained 50 µL of radiolabeled nanoparticles to which 300 µL of saline was added and the 
mixture was sonicated for 1 minute and centrifuged as described before. This process was 
repeated 5 times until no more unbound 99Tc-DPA-ale was detected in the filtrates. The total 
radioactivity in the filtrates and SPIONs solution was measured to determine the 
radiolabeling yield (36%). DLS performed after conjugation confirmed colloidal stability of 
ferucarbotran.  
SPECT/CT imaging. Prior to injections and imaging, female BALB/c mice (6-8 weeks) were 
anesthetized with isoflurane and oxygen mixture for the duration of the experiment and 
sacrificed by cervical dislocation at the end of the imaging session. All injections were done 
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intravenously through the tail vein using 0.3 mL insulin syringes. For the FVF (+) group (n = 
5), mice were injected with 100 µL of FVF solution at a dose of 15 mg/kg followed by 100 
µL of the 99Tc-DPA-ale-ferucarbotran conjugate (1.76mgFe/kg, 15-30 MBq of 99mTc) after 2-
10 minutes. For the FVF (-) group (n = 5), mice were treated with 100 µL of PBS along with 
100 µL of radiolabeled ferucarbotran. Immediately after the injections the mice were imaged 
with SPECT/CT. SPECT/CT images were obtained with a NanoSPECT/CT PLUS preclinical 
animal scanner (Mediso, Hungary) equipped with four heads, each with nine 1 mm pinhole 
collimators, in helical scanning mode in 20 projections over 20 minutes. The CT images were 
obtained with a 45 kV peak X-ray source, 1000 ms exposure time in 180 projections over 10 
minutes. Images were reconstructed in a 256 × 256 matrix using the HiSPECT (Scivis 
GmbH) reconstruction software package, and fused using InVivoScope (IVS) software 
(Bioscan, France). All the images were analyzed using VivoQuantTM software (inviCRO, 
USA), which enables the co-registration of SPECT-CT images. Scale bars represent the range 
between the minimum (bottom) and maximum (top) image signal intensity of their respective 
SPECT (color) and CT (greyscale) images 
Radiolabeling of ferucarbotran with zirconium-89 (89Zr). Radiolabelling with 89Zr was 
performed following a published method.65 Zirconium-89-oxalate (89Zr4+ in 1M oxalic acid, 
PerkinElmer) 16 µL, 33 MBq was added to an Eppendorf tube.  Chelex-treated water (200 
µL) was then added and the pH raised to 8 using 1M Na2CO3 (aq.). This step was performed 
cautiously as acid neutralization with Na2CO3 generates CO2 gas and base must be added 
carefully to avoid loss of radioactivity. Chelex-treated water was again added (200 µL), 
followed by the addition of ferucarbotran (52 µL, 58 mgFe/mL).  The mixture was then 
vortexed briefly and then incubated at 100 °C for 1 h. The reaction was allowed to cool to 
room temperature and DTPA (50 µL, 10 mM (pH 7.5) was added and left to stir at room 
temperature for 30 minutes. After which time, the nanoparticle mixture was purified using 
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size exclusion chromatography (SEC) (PD-10 Sephadex, G25) and eluted with fractions of 
sterile saline (recovery = 78%). 89Zr-ferucarbotran was diluted to 260 µL using sterile saline. 
The conjugate was then characterized using dynamic light scattering (DLS) (Supplementary 
Table S6). 
Radiolabeling of perimag®-COOH with zirconium-89 (89Zr). Radiolabelling with 89Zr  was 
performed following a published method.65 Zirconium-89-oxalate (89Zr4+ in 1M oxalic acid, 
PerkinElmer) 26 µL, 35.6 MBq was added to an Eppendorf tube.  Chelex-treated water (200 
µL) was then added and the pH raised to 8 using 1M Na2CO3 (aq.); base was added carefully 
to avoid loss of radioactivity. Chelex-treated water was again added (170 µL), followed by 
the addition of perimag®-COOH (20 µL, 18.2 mgFe/mL).  The mixture was then vortexed 
briefly and incubated at 100 °C for 60 minutes. The reaction was allowed to cool to room 
temperature and DTPA (50 µL, 10 mM (pH 7.5)) was added and left to stir at room 
temperature for 30 minutes.  After which time, the nanoparticle mixture was purified using 
size exclusion chromatography (SEC) (PD10 Sephadex, G25) and eluted with fractions of 
sterile saline (recovery = 81%). 89Zr-Perimag®-COOH was diluted to 260 µL using sterile 
saline. The conjugate was then characterized using DLS (Supplementary Table S6). 
PET/CT imaging. C57BL/6 mice were injected with 100 µL 89Zr-ferucarbotran or 89Zr-
perimag®-COOH solution (1.76 mgFe/kg), preceded by, or at the same time as, 100 µL of 
PBS or FVF (15 mg/kg, in PBS). At pre-set time points following injection of SPIONs, mice 
were anaesthetized with isoflurane (2% in oxygen) and placed on the preheated bed of the 
scanner (set at 38 ̊C). Whole body static PET scans were acquired using nanoScan PET/CT 
(Mediso, Budapest, Hungary) followed by CT image acquisition. PET images were acquired 
using 1-5 coincidence mode and recorded for 20 minutes. CT images were acquired using a 
50 kV peak X-ray source and 300 ms exposure time in 720 projections with an acquisition 
time of 7 minutes. Respiration rate was monitored throughout the scan. PET images were 
 
31 
reconstructed using Tera-TomoTM 3D PET reconstruction software (Mediso version 2.01). 
CT images were reconstructed in voxel size of 68 x 68 x 68 mm using Nucline software 
(Mediso version 2.01). Image analysis and three-dimensional (3D) visualization were 
performed using VivoQuant software (InviCRO version 1.23patch3). Scale bars represent the 
range between the minimum (bottom) and maximum (top) image signal intensity of their 
respective PET (color) and CT (greyscale) images. 
Subcutaneous tumor implantation in C57BL/6 mice. GL261 glioma cells were grown in 
filtered Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®) supplemented with 10% 
fetal bovine serum (FBS) (Gibco®), and 1% sodium pyruvate until 80% confluent. Cells were 
detached using trypsin, and counted before being re-suspended in sterile PBS at a 
concentration of 5 x 106 cells/100 µL. Animals were anaesthetized with 2% isoflurane and 
100 µL of the cell suspension was injected into the right flank. Animals were monitored 
closely for any adverse signs following injection. Tumor growth was monitored and animals 
were used for experiments once the tumors were > 50 mm3 in volume as measured using 
callipers (approximately 2-3 weeks post implantation).  
Ex vivo biodistribution studies. Biodistribution studies were carried out in accordance with 
the British Home Office regulations governing animal experimentation. The mice from the 
imaging studies were used for the biodistribution studies. Mice under anesthesia were culled 
by cervical dislocation and the organs of interest were harvested. Each sample was weighed 
and counted with a gamma counter (LKB compugamma for 99mTc studies, Wizard 2480 
PerkinElmer for 89Zr studies), together with standards prepared from a sample of the 
radiolabeled SPIONs. The percent of injected dose per gram (%ID/g) of tissue was calculated 
for each tissue type.   
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Blood clearance and pharmacokinetics experiments. To assess the blood clearance and 
calculate pharmacokinetic data, blood samples were collected from the tail using 20 µL 
heparinized capillary tubes. Each sample was weighed and counted with a gamma counter 
(LKB compugamma for 99mTc studies, Wizard 2480 PerkinElmer for 89Zr studies), together 
with standards prepared from a sample of the radiolabeled SPIONs. For 99mTc-ferucarbotran 
studies, blood samples were obtained at 3, 15, 35, 52, 67, 82, 93 and 152 minutes post 
injection; for 89Zr-ferucarbotran, samples were taken at 5, 10, 20, 40, 60 and 180 minutes post 
injection; and for 89Zr-perimag®-COOH studies, blood samples were obtained at 10, 20, 40, 
60 and 80 minutes post SPION injection. To calculate the pharmacokinetic parameters, the 
%ID/g values obtained from gamma counting the blood samples were plotted against time 
and the data was fitted to a two-compartment model using Graphpad Prism 7 (Two phase 
decay non-linear regression). 
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